Back to homepage


Presubmission enquiry

Please send an email directly to the Editor-in-Chief about manuscript suitability, or for any other journal matter. You may attach a draft of your manuscript or the abstract if you wish. The Editor-in-Chief will respond, normally in 24 hours.


Please send your manuscript and all other attachments by email to the Editor-in-Chief at:
Please use the Submission Checklist below and send a covering letter, the manuscript and additional information. Upon submission, the Editor-in-Chief will assess the suitability of the manuscript for the journal and send a response to you within 24 hours.

Submission checklist

Elements to send – you must send these all at the same time to avoid delays and repeated requests for items:;

  1. Cover letter prepared – following our Covering Letter Guidelines (below)
  2. Manuscript including figures, tables and supplementary data – prepared following our Manuscript Preparation Guidelines (below)
  3. DIC Terms and Conditions of Publication  – one copy only from corresponding author on behalf of all the authors
  4. DIC Disclosure of Potential Conflicts of Interest form** – one copy for each author

Cover Letter guidelines

  • Address the letter to the ‘Editor-in-Chief’.
  • Include a full statement about all submissions and previous reports that might be regarded as redundant publication of the same or similar work. Any such work should be referred to specifically and referenced in the new paper. Copies of such material should be included with the submitted paper to help the Editor address the situation.
  • If the manuscript has been submitted previously to another journal, it is helpful to include the other editor and peer reviewers’ comments with the submitted manuscript, along with the authors’ responses to those comments. Submitting previous communications may expedite the peer review process.
  • A statement that the manuscript has been read and approved by all the authors and that each author believes that the manuscript represents honest work.
  • The letter should give any additional information that may be helpful to the Editor-in-Chief. 
  • If appropriate, include a statement that confirms that the article complies with GPP3.
  • Include the name of any Drugs in Context Editorial Board member who is referring this article to the journal (if applicable).

Manuscript preparation guidelines

Please consult The International Committee of Medical Journal Editors (ICMJE) document on how to prepare a manuscript for submission. Note that we use iThenticate to check for plagiarism and text recycling.

You should submit a well-structured Word document (.doc, .docx) organised into the following sections:

  1. Title page
    1. Preferred spelling (US or UK)
    2. Article type
    3. Article title
    4. Running head/title – no more than 60 characters
    5. List of authors and contributors, and their affiliations. NB. Drugs in Context follows the guidelines of the ICMJE for authorship and contributorship, found here
    6. Corresponding author details including full name, affiliation and email address
    7. Trial registration number – if applicable
  2. Abstract – an abstract (250 words) is required only for Original Research and Review articles. For Original Research articles, please use a structured abstract (Background, Methods, Results, Conclusion). You may use an unstructured abstract for a review article if you prefer. 
  3. Keywords – up to 8 MeSH compliant keywords
  4. Abbreviations: please explain all abbreviations on first instance in the main text, figures and tables
  5. Introduction –  Include essential background information and the objectives of your study or review.
  6. Methodsfor original research: include clear methodology. The trial registration number must be included. Also, include a statement that the research was approved or exempted by a review committee (state its name and location).  If no formal ethics committee was available, include a statement to show that the research was conducted according to the principles of the Declaration of Helsinki. Details of patient consent must be included in the manuscript. Research studies using human or animal subjects: trial’s design, conduct, and reporting of results must conform to Good Clinical Practice guidelines (e.g. Good Clinical Practice in Food and Drug Administration (FDA)-Regulated Clinical Trials (USA), Medical Research Council Guidelines for Good Clinical Practice in Clinical Trials (UK)), World Medical Association (WMA) Declaration of Helsinki. Include clear description about choice of statistical methods.
  7. Methodsfor review articles: include the scope of your literature search.
  8. Results – concise. Use tables and figures if needed to clarify things. Clear presentation of statistics.
  9. Discussion/Conclusions – make sure the conclusions you make are backed up by your research/review. All study or review limitations must be addressed in this section. (Include an abbreviated form of the limitations in your Abstract as well.)
  10. Contributions – describe how the listed authors contributed towards the final manuscript.
  11. Disclosure and potential conflicts of interest – this section should contain the same information as your completed Conflicts of Interest form.
  12. Acknowledgments – include any assistance from medical writers and/or companies here. Also include anyone who provided technical assistance or statistical analysis, took care of the animals, or provided reagents or equipment. Please indicate here if the results of this study were presented in another form, such as a poster or abstract or at a symposium.
  13. Funding declaration – please declare if the study was funded and by whom. Please also declare if any funds were provided for medical writing assistance.
  14. References – we use AMA style with the addition of DOI numbers – see additional information below
  15. Tables – see additional information below
  16. Figures – see additional information below

Use of drug names

Replace ™ and ® symbols after proprietary drug names at point of first use in the introduction with asterisk, dagger † and double dagger ‡ marks and insert corresponding footnotes indicating that the drug is a registered trademark giving the manufacturer’s name, city and country. Omit further use of ™ and ® symbols. In the remainder of the manuscript, use generic names in preference to proprietary names. Where the use of proprietary names is necessary to distinguish between formulations, put the proprietary name in brackets after the generic name.


Research should be reported in the past tense, but conclusions and discussions should be in the present tense.

References – we use AMA reference style

  1. We use AMA reference style with the addition of DOI numbers if available. (This is new from May 2018) A 30-day free trial of the AMA style guide is available here.
  2. Please consult this ‘Tip Sheet‘ from New York Medical College to give you a brief summary of requirements. (Note journal names should be in italics!)
  3. Endnote users: please use this Drugs in Context plug-in to add to your Endnote library. You will then be able to format your references in our style.
  4. Include a complete DOI for each reference. DOIs are often part of an article’s PubMed record or you can interrogate the CrossRef database here: After a given reference, add the DOI formatted like this:
  5. If necessary provide URLs for certain references and include a ‘last accessed’ date. Please note that providing a link and a ‘last accessed’ date means that you have checked that the link is live and functioning and that the material found there, at the hyperlink destination, relates to the reference. Referenced material at URLs is often found to be out of date. Please carefully check the material found at the links, especially checking for updates of clinical guidelines etc. 
  6. Personal communications, papers in preparation, unpublished observations should be referred to in brackets in the text and not listed as references e.g. …at these conditions the core temperature of the reactor remains stable (A Einstein, personal communication).


  1. Psotka MA, Teerlink JR. Direct myosin activation by omecamtiv mecarbil for heart failure with reduced ejection fraction. Handb Exp Pharmacol. 2017;243:465-490.
  2. Packer M, O’Connor C, McMurray JJV, et al. Effect of ularitide on cardiovascular mortality in acute heart failure. N Engl J Med. 2017;376(20):1956-1964.
  3. Martinod  E, Chouahnia  K, Radu  DM,  et al.  Feasibility of bioengineered tracheal and bronchial reconstruction using stented aortic matrices  [published online May 20, 2018].  JAMA. http://doi:10.1001/jama.2018.4653
  4. Centers for Disease Control and Prevention.  Data and statistics: occurrence of Down syndrome in the United States. Accessed April 2, 2018.

Figures – additional information

Drugs in Context does not redraw figures to save time and reduce errors. Please submit figures in two file formats:

  1. Application format: for example, if the graphic was created in Illustrator, submit the Illustrator file.
  2. Jpeg format: export the graphic from the application that was used to create it to provide the graphic as a high-resolution jpeg. High resolution is 300dpi or more.

Figures should be cited within the text like this (Figure 1). Place all figures together at the end of the text and ensure a caption is provided for each one. Use alphabet letters for symbols. Please explain all non-standard abbreviations in the legend (even if you have explained it in the text).

Tables – additional information

Please provide Tables as part of your Word document. Tables should be cited within the text like this (Table 1). Place all tables together at the end of the text and ensure a caption is provided for each one. Use alphabet letters for symbols. Please explain all non-standard abbreviations in a footnote (even if you have explained it in the text).

Supplementary files

Clearly label any extra files and specify what you are sending and why in the covering letter 

Further questions:

Please contact the Editor-in-Chief if you have any other questions.

**Please note: If the DIC Disclosure of Potential Conflicts of Interest form does not download or load easily, it means you need to update to the latest version of Acrobat Reader (which is the DC version), which is available for download here.